CR20150665A - Complemento de hierro - Google Patents

Complemento de hierro

Info

Publication number
CR20150665A
CR20150665A CR20150665A CR20150665A CR20150665A CR 20150665 A CR20150665 A CR 20150665A CR 20150665 A CR20150665 A CR 20150665A CR 20150665 A CR20150665 A CR 20150665A CR 20150665 A CR20150665 A CR 20150665A
Authority
CR
Costa Rica
Prior art keywords
iron
component
zinc
chelating
compounds
Prior art date
Application number
CR20150665A
Other languages
English (en)
Inventor
Jonathan David Bortz
Original Assignee
Amip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amip Llc filed Critical Amip Llc
Publication of CR20150665A publication Critical patent/CR20150665A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Un sistema de dosis suministrable oralmente comprende (a) hierro en una forma de uno o más compuestos y/o complejos, grado de hierro aceptable fisiológicamente; y (b) un agente para mitigar uno o más efectos adversos gastrointestinales de hierro no absorbido, el agente que comprende uno o tanto el componente de zinc y un componente quelante, el componente de zinc si está presente comprende uno o más compuestos y/o complejos de zinc aceptables fisiológicamente y el componente quelante si está presente comprende un compuesto quelante de hierro formulado para liberación distal al sitio primario de absorción de hierro en el duodeno.
CR20150665A 2013-06-06 2015-12-17 Complemento de hierro CR20150665A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361831879P 2013-06-06 2013-06-06
PCT/US2014/039738 WO2014197250A1 (en) 2013-06-06 2014-05-28 Iron supplement

Publications (1)

Publication Number Publication Date
CR20150665A true CR20150665A (es) 2016-02-24

Family

ID=52005976

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150665A CR20150665A (es) 2013-06-06 2015-12-17 Complemento de hierro

Country Status (12)

Country Link
US (2) US11331287B2 (es)
EP (1) EP3003328B1 (es)
AU (1) AU2014275307B2 (es)
BR (1) BR112015029468A8 (es)
CA (1) CA2913413C (es)
CR (1) CR20150665A (es)
ES (1) ES2895044T3 (es)
GT (1) GT201500328A (es)
MX (1) MX377119B (es)
PL (1) PL3003328T3 (es)
WO (1) WO2014197250A1 (es)
ZA (1) ZA201508363B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10653658B2 (en) 2015-08-11 2020-05-19 Akeso Biomedical, Inc. Biofilm inhibiting compositions enhancing weight gain in livestock
DK3334440T3 (en) * 2015-08-11 2021-07-26 Akeso Biomedical Inc Biofilm inhibiting compositions enhancing weight gain in livestock
US11083738B2 (en) * 2017-09-28 2021-08-10 Natals, Inc. Dietary nutrient compositions
MD3684344T2 (ro) 2017-10-25 2025-09-30 Chiesi Farm Spa Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora
US20220265586A1 (en) * 2019-06-10 2022-08-25 Ponce De Leon Health Designated Activity Company Sustained-release compositions of alpha-ketoglutarate
AU2022227671A1 (en) * 2021-02-24 2023-09-07 MoxxiTech, LLC Compositions and methods for treating canine parvovirus infection
US12016851B2 (en) * 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016850B2 (en) * 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91047A (en) 1989-07-19 1993-06-10 Yissum Res Dev Co Zinc complexes for the treatment of free radical- induced diseases
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5516925A (en) 1994-08-23 1996-05-14 Albion International, Inc. Amino acid chelates having improved palatability
US6521247B1 (en) * 1999-08-13 2003-02-18 Warner Chilcott Laboratories Ireland Limited Dual iron containing nutritional supplement
US7160855B2 (en) * 2002-03-14 2007-01-09 Children's Hospital & Research Center At Oakland Enhancement of iron chelation therapy
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
CN1965697A (zh) 2005-11-15 2007-05-23 王健柏 营养补血保健饮用制品
US8007846B2 (en) 2006-01-18 2011-08-30 Albion International, Inc. Mixed amino acid/mineral compounds having improved solubility
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
WO2009032699A1 (en) * 2007-08-29 2009-03-12 Drugtech Corporation Anti-proliferative combinations
WO2010136839A1 (en) 2009-05-29 2010-12-02 Carlo Ghisalberti Use of deferoxamine and related compounds in targeted delivery forms to treat an inflammatory bowel disease
CN101744120B (zh) 2009-12-25 2012-04-11 河北农业大学 乳仔猪微量元素预混料
CN102318764B (zh) 2011-08-30 2014-04-02 武汉天龙饲料有限公司 一种无抗仔猪教槽料及其制备方法
AU2012311964B2 (en) * 2011-09-22 2016-09-22 Amip Buffered upper GI absorption promoter

Also Published As

Publication number Publication date
PL3003328T3 (pl) 2022-01-24
US11331287B2 (en) 2022-05-17
BR112015029468A2 (pt) 2017-07-25
CA2913413A1 (en) 2014-12-11
MX2015016660A (es) 2016-07-26
ZA201508363B (en) 2017-09-27
EP3003328A4 (en) 2017-05-03
WO2014197250A1 (en) 2014-12-11
EP3003328A1 (en) 2016-04-13
EP3003328B1 (en) 2021-07-28
AU2014275307B2 (en) 2017-06-15
BR112015029468A8 (pt) 2020-03-17
ES2895044T3 (es) 2022-02-17
GT201500328A (es) 2017-12-14
MX377119B (es) 2025-03-07
AU2014275307A1 (en) 2015-12-10
US20220233476A1 (en) 2022-07-28
US20140364491A1 (en) 2014-12-11
CA2913413C (en) 2021-11-23

Similar Documents

Publication Publication Date Title
CR20150665A (es) Complemento de hierro
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
MX2019009853A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
WO2015095811A8 (en) Combination therapy with neoantigen vaccine
BR112015022047A2 (pt) métodos para tratar câncer de bexiga
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
PH12016500072B1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
UA118177C2 (uk) Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
MX389250B (es) Compuestos inhibidores de isocitrato deshidrogenasa 2 (idh2) y el uso de los mismos
CL2013000713A1 (es) Compuestos pirazin-2-cabonil-imino-1,3,8-triaza-espiro-[4.5]-decan-sustituidos, bloqueadores del canal de sodio epitelial (enac); composicion farmaceutica que los incluye; metodo de prevencion o tratamiento; y su uso para tratar una enfermedad o condicion mediada por el bloqueo del canal de sodio epitelial.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
PH12015501783A1 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
HRP20191000T1 (hr) Spojevi za vezanje nhe3 i metode inhibiranja transporta fosfata
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
CR20150505A (es) Derivado de dihidropiridazin-3,5-diona
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
ECSP15051434A (es) Composición farmacéutica de dosis baja
AR091351A1 (es) Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.
WO2014182789A3 (en) Radiomitigating pharmaceutical formulations